JP2025507947A5 - - Google Patents

Info

Publication number
JP2025507947A5
JP2025507947A5 JP2024552359A JP2024552359A JP2025507947A5 JP 2025507947 A5 JP2025507947 A5 JP 2025507947A5 JP 2024552359 A JP2024552359 A JP 2024552359A JP 2024552359 A JP2024552359 A JP 2024552359A JP 2025507947 A5 JP2025507947 A5 JP 2025507947A5
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
pyridine
solvate
acceptable salt
amine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024552359A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025507947A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2023/063338 external-priority patent/WO2023168203A1/en
Publication of JP2025507947A publication Critical patent/JP2025507947A/ja
Publication of JP2025507947A5 publication Critical patent/JP2025507947A5/ja
Pending legal-status Critical Current

Links

JP2024552359A 2022-03-04 2023-02-27 Mekキナーゼ阻害剤 Pending JP2025507947A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263316607P 2022-03-04 2022-03-04
US63/316,607 2022-03-04
PCT/US2023/063338 WO2023168203A1 (en) 2022-03-04 2023-02-27 Inhibitors of mek kinase

Publications (2)

Publication Number Publication Date
JP2025507947A JP2025507947A (ja) 2025-03-21
JP2025507947A5 true JP2025507947A5 (cg-RX-API-DMAC7.html) 2026-03-06

Family

ID=85704077

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024552359A Pending JP2025507947A (ja) 2022-03-04 2023-02-27 Mekキナーゼ阻害剤

Country Status (7)

Country Link
US (3) US11780862B2 (cg-RX-API-DMAC7.html)
EP (1) EP4486750A1 (cg-RX-API-DMAC7.html)
JP (1) JP2025507947A (cg-RX-API-DMAC7.html)
CN (1) CN119137130A (cg-RX-API-DMAC7.html)
AR (1) AR128622A1 (cg-RX-API-DMAC7.html)
TW (1) TW202342018A (cg-RX-API-DMAC7.html)
WO (1) WO2023168203A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202342018A (zh) 2022-03-04 2023-11-01 美商奇奈特生物製藥公司 Mek激酶抑制劑
WO2024220427A1 (en) * 2023-04-17 2024-10-24 Kinnate Biopharma Inc. Treatment of cancer with a mek kinase inhibitor
WO2025032211A1 (en) 2023-08-09 2025-02-13 Pierre Fabre Medicament Treatment of cancer with a raf inhibitor

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6334997B1 (en) 1994-03-25 2002-01-01 Isotechnika, Inc. Method of using deuterated calcium channel blockers
KR100477070B1 (ko) 1994-03-25 2006-04-21 이소테크니카 인코포레이티드 중수소화작용에의한의약품의효능강화법
US5525625A (en) 1995-01-24 1996-06-11 Warner-Lambert Company 2-(2-Amino-3-methoxyphenyl)-4-oxo-4H-[1]benzopyran for treating proliferative disorders
UA73073C2 (uk) 1997-04-03 2005-06-15 Уайт Холдінгз Корпорейшн Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція
ATE344791T1 (de) 1997-07-01 2006-11-15 Warner Lambert Co 2-(4-brom or 4-iod phenylamino)benzoesäurederivate und ihre anwendung als mek-inhibitoren
ES2229515T3 (es) 1997-07-01 2005-04-16 Warner-Lambert Company Llc Derivados 4-bromo o 4-yodo del acido fenilamino benzhidroxamico y su uso como inhibidores de la mek.
ID30439A (id) 1999-01-13 2001-12-06 Warner Lambert Co Benzoheterosiklus dan penggunaannya sebagai penghambat mek
BR9916857A (pt) 1999-01-13 2001-12-04 Warner Lambert Co 4 heteroaril diarilaminas
JP2002534515A (ja) 1999-01-13 2002-10-15 ワーナー−ランバート・カンパニー 1−複素環置換されたジアリールアミン
CA2349832A1 (en) 1999-01-13 2000-07-20 Warner-Lambert Company Benzenesulfonamide derivatives and their use as mek inhibitors
CA2348236A1 (en) 1999-01-13 2000-07-20 Stephen Douglas Barrett 4-arylamino, 4-aryloxy, and 4-arylthio diarylamines and derivatives thereof as selective mek inhibitors
AU2482800A (en) 1999-01-13 2000-08-01 Warner-Lambert Company Sulphohydroxamic acids and sulphohydroxamates and their use as mek inhibitors
GB9910577D0 (en) 1999-05-08 1999-07-07 Zeneca Ltd Chemical compounds
JP2003527379A (ja) 2000-03-15 2003-09-16 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー Mex阻害物質としての5−アミド置換ジアリールアミン類
AU7349801A (en) 2000-07-19 2002-01-30 Warner Lambert Co Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids
IL149462A0 (en) 2001-05-09 2002-11-10 Warner Lambert Co Method of treating or inhibiting neutrophil chemotaxis by administering a mek inhibitor
BR0307060A (pt) 2002-01-23 2004-10-26 Warner Lambert Co ésteres hidroxamato do ácido n-(fenil 4-substituìdo)-antranìlico
WO2003077855A2 (en) 2002-03-13 2003-09-25 Array Biopharma, Inc N3 alkylated benzimidazole derivatives as mek inhibitors
SG2013013339A (en) 2002-03-13 2014-12-30 Array Biopharma Inc N3 alkylated benzimidazole derivatives as mek inhibitors
GB0215823D0 (en) 2002-07-09 2002-08-14 Astrazeneca Ab Quinazoline derivatives
US20050004186A1 (en) 2002-12-20 2005-01-06 Pfizer Inc MEK inhibiting compounds
JP4931419B2 (ja) 2003-09-19 2012-05-16 中外製薬株式会社 新規4−フェニルアミノ−ベンズアルドオキシム誘導体並びにそのmek阻害剤としての使用
MY144232A (en) 2004-07-26 2011-08-15 Chugai Pharmaceutical Co Ltd 5-substituted-2-phenylamino benzamides as mek inhibitors
ES2444866T3 (es) 2004-10-20 2014-02-27 Merck Serono Sa Derivados de 3-arilamino piridina
NZ567140A (en) 2005-10-07 2011-09-30 Exelixis Inc Azetidines as MEK inhibitors for the treatment of proliferative diseases
WO2007123939A2 (en) 2006-04-19 2007-11-01 Laboratoires Serono S.A. Novel arylamino n-heteraryls as mek inhibitors
EP2279166A1 (en) 2008-04-22 2011-02-02 Bayer Schering Pharma Aktiengesellschaft Substituted phenoxybenzamides
AU2009279940B2 (en) 2008-08-04 2014-01-16 Merck Patent Gmbh Novel phenylamino isonicotinamide compounds
WO2012055953A1 (en) 2010-10-29 2012-05-03 Bayer Pharma Aktiengesellschaft Substituted phenoxypyridines
CN102649773A (zh) 2011-02-23 2012-08-29 苏州波锐生物医药科技有限公司 氨基芳香烃类化合物及其在制备抗恶性肿瘤药物中的用途
CN103570594A (zh) 2012-08-01 2014-02-12 苏州迈泰生物技术有限公司 二芳基胺类化合物及其在制备抗恶性肿瘤药物中的用途
WO2020088390A1 (zh) * 2018-10-29 2020-05-07 江苏先声药业有限公司 作为第四代egfr抑制剂的嘧啶吡唑类化合物
CN113660931B (zh) 2018-11-20 2024-10-11 恩福莱克逊治疗有限公司 用于治疗皮肤癌的芳基苯胺和杂芳基苯胺化合物
TW202342018A (zh) 2022-03-04 2023-11-01 美商奇奈特生物製藥公司 Mek激酶抑制劑

Similar Documents

Publication Publication Date Title
JP2022185107A5 (cg-RX-API-DMAC7.html)
RU2498983C2 (ru) Соединения фениламинопиримидина и их применения
JP2023524598A5 (cg-RX-API-DMAC7.html)
JP2024050527A5 (cg-RX-API-DMAC7.html)
JP2007519754A5 (cg-RX-API-DMAC7.html)
KR101585848B1 (ko) 관절염의 치료 방법
JP2010520893A5 (cg-RX-API-DMAC7.html)
JP2008517945A5 (cg-RX-API-DMAC7.html)
JP2020511452A5 (cg-RX-API-DMAC7.html)
NZ627750A (en) Carbamate compounds and of making and using same
RU2011110435A (ru) Пролекарства метилгидрофумарата, фармацетические композиции с ними и способы применения
JP2006504656A5 (cg-RX-API-DMAC7.html)
JP2018502101A5 (cg-RX-API-DMAC7.html)
JP2010535180A5 (cg-RX-API-DMAC7.html)
JP2008517926A5 (cg-RX-API-DMAC7.html)
JP2004502670A5 (cg-RX-API-DMAC7.html)
CA2418868A1 (en) 4-phenyl-pyridine derivatives as neurokinin-1 receptor antagonists
JP2012530765A5 (cg-RX-API-DMAC7.html)
JP2024518556A5 (cg-RX-API-DMAC7.html)
JP2004520292A5 (cg-RX-API-DMAC7.html)
JP2022553351A5 (cg-RX-API-DMAC7.html)
RU2009144113A (ru) Ингибиторы фермента диацилглицерин о-ацилтрансферазы типа 1
JP2006506380A5 (cg-RX-API-DMAC7.html)
RU2011140869A (ru) Пиперазиновое соединение, ингибирующее простагландин-d-синтазу
JP2013525262A5 (cg-RX-API-DMAC7.html)